These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8957728)

  • 1. Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer.
    Messori A; Bonistalli L; Costantini M; Trallori G; Tendi E
    J Clin Gastroenterol; 1996 Dec; 23(4):269-74. PubMed ID: 8957728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide+methotrexate+fluorouracil in patients with node-positive breast cancer.
    Messori A; Becagli P; Trippoli S; Tendi E
    Eur J Clin Pharmacol; 1996; 51(2):111-6. PubMed ID: 8911873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany.
    Monz BU; König HH; Leidl R; Staib L; Link KH
    Pharmacoeconomics; 2003; 21(10):709-19. PubMed ID: 12828493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis.
    Norum J; Vonen B; Olsen JA; Revhaug A
    Ann Oncol; 1997 Jan; 8(1):65-70. PubMed ID: 9093709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Final results of a randomized clinical trial of adjuvant intraportal chemotherapy for colorectal cancer: Intraportal Chemotherapy for Colorectal Cancer Group].
    Yamamura T; Yabe K; Oka H; Kouzuma T; Kawahara H; Wakayama T; Sugiura A; Hagiwara M; Ohdate K; Miyajima N; Maeda C; Okamura R; Miyahara T; Moriyama Y; Yamaguchi S; Gunji A;
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1765-71. PubMed ID: 12402427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.
    Nordlinger B; Rougier P; Arnaud JP; Debois M; Wils J; Ollier JC; Grobost O; Lasser P; Wals J; Lacourt J; Seitz JF; Guimares dos Santos J; Bleiberg H; Mackiewickz R; Conroy T; Bouché O; Morin T; Baila L; van Cutsem E; Bedenne L
    Lancet Oncol; 2005 Jul; 6(7):459-68. PubMed ID: 15992694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recent advances is surgical adjuvant chemotherapy for colorectal cancer].
    Kodaira S; Shatari T; Nozawa K
    Gan To Kagaku Ryoho; 2000 Dec; 27(14):2201-8. PubMed ID: 11142163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma.
    Smith RD; Hall J; Gurney H; Harnett PR
    Med J Aust; 1993 Mar; 158(5):319-22. PubMed ID: 8474372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma.
    de Souza P
    Med J Aust; 1993 Jun; 158(12):866. PubMed ID: 8326905
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial.
    Shiroiwa T; Takeuchi T; Fukuda T; Shimozuma K; Ohashi Y
    Value Health; 2012; 15(2):255-60. PubMed ID: 22433756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early hematological toxicity of adjuvant perioperative intraportal and intravenous chemotherapy with fluorouracil, mitomycin and heparin in colorectal cancer. Swiss Group for Clinical Cancer Research.
    Weber W; Maibach R; Laffer U; Metzger U; Egeli R; Lorenz M; Aeberhard P; Dupont-Lampert V; Nöthiger F; Rüed T
    Anticancer Res; 1995; 15(5B):2197-200. PubMed ID: 8572624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
    Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
    Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU.
    Rougier P; Nordlinger B
    Ann Oncol; 1993; 4 Suppl 2():21-8. PubMed ID: 8353101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma.
    Messori A; Becagli P; Trippoli S; Tendi E
    Eur J Cancer; 1997 Aug; 33(9):1373-9. PubMed ID: 9337677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Following curative resection of colorectal cancer, portal chemotherapy especially benefits non-transfused patients].
    Harder F; Laffer U; Berres M; Jäggi P; Metzger U
    Chirurg; 1990 Apr; 61(4):280-5. PubMed ID: 2112083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost effectiveness analysis of two adjuvant regimens in the treatment of colorectal cancer: an interpretation of the MOSAIC Study].
    Rebesco B; Cantagalli E; Amalfitano ME
    Tumori; 2005; 91(6):suppl 1-10. PubMed ID: 16457161
    [No Abstract]   [Full Text] [Related]  

  • 17. Randomized multicenter trial of adjuvant intraportal chemotherapy for colorectal cancer (SAKK 40/81). An interim report.
    Metzger U; Laffer U; Aeberhard P; Arigoni M; Arma S; Barras J; Egeli R; Martinoli S; Mueller W; Schweizer W
    Acta Chir Scand; 1990; 156(6-7):467-74. PubMed ID: 2114722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment.
    Brown ML; Nayfield SG; Shibley LM
    J Natl Cancer Inst; 1994 Mar; 86(6):424-30. PubMed ID: 8120916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases.
    Ercolani G; Cucchetti A; Cescon M; Peri E; Brandi G; Del Gaudio M; Ravaioli M; Zanello M; Pinna AD
    Eur J Cancer; 2011 Oct; 47(15):2291-8. PubMed ID: 21652204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.